论文部分内容阅读
目的探讨帕金森病(PD)患者血清人软骨糖蛋白39(YKL-40)水平的改变及其与病情和认知功能的相关性。方法用ELISA法给63例PD患者和60名正常对照者进行血清YKL-40水平检测,以及蒙特利尔认知评估(Mo CA)量表评分。并给PD患者进行统一PD评定量表(UPDRS)Ⅰ、Ⅱ、Ⅲ评分,评定病情。对PD患者的血清YKL-40水平与UPDRSⅠ、Ⅱ、Ⅲ评分、病程及Mo CA量表进行相关性分析。结果 PD组的血清YKL-40水平[(3.717±0.1015)ng/ml]明显高于正常对照组[(2.919±0.1827)ng/ml](P<0.001)。PD患者的血清YKL-40水平与UPDRSⅠ无相关性(r=0.21,P>0.05),与UPDRSⅡ、Ⅲ评分呈正相关(r=0.9251,r=0.7767;均P<0.0001),与PD患者的病程亦呈正相关(r=0.4323,P<0.01),与Mo CA量表评分呈负相关(r=-0.6985,P<0.0001)。结论 PD患者的血清YKL-40水平显著增高,并与病情和认知功能密切相关。YKL-40可成为PD诊断和病情判断的生物学指标。
Objective To investigate the changes of serum level of human choroidal gonad 39 (YKL-40) in patients with Parkinson’s disease (PD) and its relationship with disease status and cognitive function. Methods Serum YKL-40 levels were measured in 63 patients with PD and 60 normal controls by ELISA and the Montreal Cognitive Assessment (MoCA) scale. PD patients were also evaluated by the Unified PD Rating Scale (UPDRS) Ⅰ, Ⅱ, Ⅲ. The correlation between serum YKL-40 levels and UPDRS Ⅰ, Ⅱ, Ⅲ scores, duration of disease and Mo CA scale were analyzed. Results The level of serum YKL-40 in PD group [(3.717 ± 0.1015) ng / ml] was significantly higher than that in the normal control group [(2.919 ± 0.1827) ng / ml] (P <0.001). The level of serum YKL-40 in PD patients was not correlated with UPDRSⅠ (r = 0.21, P> 0.05), but positively correlated with UPDRSⅡ and Ⅲ (r = 0.9251, r = 0.7767; all P <0.0001) (R = 0.4323, P <0.01), but negatively correlated with MoCA scale (r = -0.6985, P <0.0001). Conclusion The serum level of YKL-40 in patients with PD is significantly higher than that in patients with PD, and is closely related to the disease and cognitive function. YKL-40 can become a biological indicator of PD diagnosis and disease judgment.